Arcus Biosciences CEO Juan Jaen 12月4日售出2.05M美元股份, Arcus Biosciences CEO Juan Jaen sold $2.05M in shares Dec. 4 amid mixed Q3 results and rising institutional ownership.

Arcus生物科学组织主席Juan Jaen于2025年12月4日出售了82 997股, 价值约205万美元, Arcus Biosciences President Juan Jaen sold 82,997 shares on December 4, 2025, for about $2.05 million, reducing his stake by 8%. 该公司报告了Q3收入,每股损失1.27美元,略高于预期,比上一年增加收入2 600万美元。 The company reported Q3 earnings with a loss of $1.27 per share, slightly better than expected, and $26 million in revenue, up from the prior year. 机构投资者现在拥有92.89%的股份,Tema Etfs LLC在问题2中的股权增加了291.2%。 Institutional investors now hold 92.89% of shares, with Tema Etfs LLC increasing its stake by 291.2% in Q2. 股价收盘时为25.50美元,12个月的价格范围为6.50美元至26.40美元,共识评级为"中等买入". The stock closed at $25.50, with a 12-month range of $6.50 to $26.40 and a "Moderate Buy" consensus rating. 该公司的输油管在临床试验中包括两项抗TIGIT抗体,用于治疗先进的癌症。 The company’s pipeline includes two anti-TIGIT antibodies in clinical trials for advanced cancers.